“Institutional Cost Savings through Dose Banding Strategy of Pembrolizumab in Oncology Patients: A Real-World Data Analysis”. Universitas Scientiarum, Nov. 2025, p. S19, https://doi.org/10.11144/Javeriana.SCSI30.icst.